FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136249370> ?p ?o ?g. }

• W3136249370 abstract "Background: Secondary prevention in patients with myocardial infarction (MI) is critically important to prevent ischaemic heart failure and reduce social burden. Pioglitazone improves vascular dysfunction and prevents coronary atherosclerosis, mainly via anti-inflammatory and antiatherogenic effects by enhancing adiponectin production in addition to antihyperglycemic effects, thus suggesting that pioglitazone attenuates cardiovascular events in patients with mild (HbA1c levels < 6·5%) diabetes mellitus (DM). Therefore, we evaluated the effects of pioglitazone on cardiovascular events in patients with both previous MI and mild DM. Methods: In this multicentre, prospective, randomised, open, blinded-endpoint trial of PPAR study, we randomly assigned 630 patients with mild DM with a history of MI to undergo either DM therapy with (pioglitazone group) or without (control group) pioglitazone. DM was diagnosed using the 75-g oral glucose tolerance test, and mild DM was defined if HbA1c level was < 6·5%. The primary endpoint was the composite of cardiovascular death and hospitalisation caused by acute MI, unstable angina, coronary revascularisation (including percutaneous coronary intervention and cardiac bypass surgery), and stroke. HbA1C levels were 5·9 and 5·8% (p = 0.71) at baseline and 6·0 and 5·8% (p < 0.01) at 2 years for the control and pioglitazone groups, respectively.Findings: The primary endpoint was observed in 14·2% and 14·1% patients in the control and pioglitazone groups during two years, respectively; the incidence of MI and stroke was 0·3% and 2·2% and 1·0% and 0·3%, respectively. Post-hoc analyses of the 7-year observation period showed that these trends became clearer. Interpretation: Pioglitazone could not reduce the occurrence of cardiovascular events in patients with mild DM and previous MI. This result contradicts the results of the IRIS trial that pioglitazone decreased cardiovascular events in stroke patients  or the results of the PROactive trial that pioglitazone decreased cardiovascular events in patients with moderate DM and macrovascular disease. Funding: The Grants of Japan Heart Foundation for PPAR study. Conflict of Interest: Dr. Asakura reports grants from Acterion Pharmaceutical Japan, grants from Boehringer Ingelheim Japan, Inc., personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Sanofi K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from MSD K.K., personal fees from Takeda Pharmaceutical Company Limited., personal fees from ONO PHARMACEUTICAL CO., LTD., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from DAIICHI SANKYO COMPANY, LIMITED , personal fees from Pfizer Japan Inc., personal fees from Astellas Amgen Biopharma, outside the submitted work. Dr. Kim has nothing to disclose. Dr. Asanuma reports grants from Japan Heart Foundation, during the conduct of the study; grants from Japan Society For The Promotion Of Science (Grants-in-Aid For Scientific Research), grants from Novartis Pharmaceuticals Corporation, grants from Mitsubishi Tanabe Pharma Corporation, personal fees from Otsuka Pharmaceutical Co,Ltd, personal fees from Kyowa Hakko Kirin Co, Ltd, personal fees from Daiichi Sankyo Company, Limited, outside the submitted work. Dr. Hamasaki has nothing to disclose. Dr. Nakama has nothing to disclose. Dr. Tsukahara reports grants from Japan Heart Foundation, during the conduct of the study. Dr. Higashino reports grants from Japan Heart Foundation, during the conduct of the study. Dr. Ishikawa reports grants from Japan Heart Foundation during the conduct of the study. Dr. Koba reports grants from Japan Heart Foundation during the conduct of the study; grants from Daiichi Sankyo Company, Ltd, personal fees from MSD K.K. outside the submitted work. Ethical Approval Statement: The study was performed following the principles of the Declaration of Helsinki and the Japanese ethical guidelines for clinical research." @default.
• W3136249370 created "2021-03-29" @default.
• W3136249370 creator A5004804871 @default.
• W3136249370 creator A5007206953 @default.
• W3136249370 creator A5008148847 @default.
• W3136249370 creator A5010321399 @default.
• W3136249370 creator A5010891326 @default.
• W3136249370 creator A5016670627 @default.
• W3136249370 creator A5017099114 @default.
• W3136249370 creator A5018410857 @default.
• W3136249370 creator A5019498837 @default.
• W3136249370 creator A5019660603 @default.
• W3136249370 creator A5020991235 @default.
• W3136249370 creator A5021537136 @default.
• W3136249370 creator A5022224155 @default.
• W3136249370 creator A5023118044 @default.
• W3136249370 creator A5024068935 @default.
• W3136249370 creator A5027282442 @default.
• W3136249370 creator A5027464368 @default.
• W3136249370 creator A5031377508 @default.
• W3136249370 creator A5034179596 @default.
• W3136249370 creator A5034729823 @default.
• W3136249370 creator A5036155456 @default.
• W3136249370 creator A5043752489 @default.
• W3136249370 creator A5044195355 @default.
• W3136249370 creator A5048941461 @default.
• W3136249370 creator A5049717476 @default.
• W3136249370 creator A5051039857 @default.
• W3136249370 creator A5054210433 @default.
• W3136249370 creator A5055701247 @default.
• W3136249370 creator A5057184445 @default.
• W3136249370 creator A5057770104 @default.
• W3136249370 creator A5058711256 @default.
• W3136249370 creator A5061755175 @default.
• W3136249370 creator A5062630492 @default.
• W3136249370 creator A5063044564 @default.
• W3136249370 creator A5064414388 @default.
• W3136249370 creator A5064669775 @default.
• W3136249370 creator A5070291128 @default.
• W3136249370 creator A5076319375 @default.
• W3136249370 creator A5078219838 @default.
• W3136249370 creator A5078395248 @default.
• W3136249370 creator A5079601936 @default.
• W3136249370 creator A5080156110 @default.
• W3136249370 creator A5080293775 @default.
• W3136249370 creator A5080389718 @default.
• W3136249370 creator A5083404665 @default.
• W3136249370 creator A5084428911 @default.
• W3136249370 creator A5089278093 @default.
• W3136249370 date "2018-01-01" @default.
• W3136249370 modified "2023-10-01" @default.
• W3136249370 title "Cardiovascular Outcomes in Patients with Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment with Pioglitazone -Reports from the Japan Working Group for the Assessment Whether Pioglitazone Protects Dm Patients Against Re-Infarction (Ppar Study)-" @default.
• W3136249370 doi "https://doi.org/10.2139/ssrn.3208358" @default.
• W3136249370 hasPublicationYear "2018" @default.
• W3136249370 type Work @default.
• W3136249370 sameAs 3136249370 @default.
• W3136249370 citedByCount "0" @default.
• W3136249370 crossrefType "journal-article" @default.
• W3136249370 hasAuthorship W3136249370A5004804871 @default.
• W3136249370 hasAuthorship W3136249370A5007206953 @default.
• W3136249370 hasAuthorship W3136249370A5008148847 @default.
• W3136249370 hasAuthorship W3136249370A5010321399 @default.
• W3136249370 hasAuthorship W3136249370A5010891326 @default.
• W3136249370 hasAuthorship W3136249370A5016670627 @default.
• W3136249370 hasAuthorship W3136249370A5017099114 @default.
• W3136249370 hasAuthorship W3136249370A5018410857 @default.
• W3136249370 hasAuthorship W3136249370A5019498837 @default.
• W3136249370 hasAuthorship W3136249370A5019660603 @default.
• W3136249370 hasAuthorship W3136249370A5020991235 @default.
• W3136249370 hasAuthorship W3136249370A5021537136 @default.
• W3136249370 hasAuthorship W3136249370A5022224155 @default.
• W3136249370 hasAuthorship W3136249370A5023118044 @default.
• W3136249370 hasAuthorship W3136249370A5024068935 @default.
• W3136249370 hasAuthorship W3136249370A5027282442 @default.
• W3136249370 hasAuthorship W3136249370A5027464368 @default.
• W3136249370 hasAuthorship W3136249370A5031377508 @default.
• W3136249370 hasAuthorship W3136249370A5034179596 @default.
• W3136249370 hasAuthorship W3136249370A5034729823 @default.
• W3136249370 hasAuthorship W3136249370A5036155456 @default.
• W3136249370 hasAuthorship W3136249370A5043752489 @default.
• W3136249370 hasAuthorship W3136249370A5044195355 @default.
• W3136249370 hasAuthorship W3136249370A5048941461 @default.
• W3136249370 hasAuthorship W3136249370A5049717476 @default.
• W3136249370 hasAuthorship W3136249370A5051039857 @default.
• W3136249370 hasAuthorship W3136249370A5054210433 @default.
• W3136249370 hasAuthorship W3136249370A5055701247 @default.
• W3136249370 hasAuthorship W3136249370A5057184445 @default.
• W3136249370 hasAuthorship W3136249370A5057770104 @default.
• W3136249370 hasAuthorship W3136249370A5058711256 @default.
• W3136249370 hasAuthorship W3136249370A5061755175 @default.
• W3136249370 hasAuthorship W3136249370A5062630492 @default.
• W3136249370 hasAuthorship W3136249370A5063044564 @default.
• W3136249370 hasAuthorship W3136249370A5064414388 @default.
• W3136249370 hasAuthorship W3136249370A5064669775 @default.
• W3136249370 hasAuthorship W3136249370A5070291128 @default.
• W3136249370 hasAuthorship W3136249370A5076319375 @default.
• W3136249370 hasAuthorship W3136249370A5078219838 @default.
• W3136249370 hasAuthorship W3136249370A5078395248 @default.
• W3136249370 hasAuthorship W3136249370A5079601936 @default.
• W3136249370 hasAuthorship W3136249370A5080156110 @default.

• next